Discovery and structure-activity relationship of N-(ureidoalkyl)-benzyl-piperidines as potent small molecule CC chemokine receptor-3 (CCR3) antagonists

被引：46

作者：

De Lucca, GV ^{[1
]}

Kim, UT ^{[1
]}

Johnson, C ^{[1
]}

Vargo, BJ ^{[1
]}

Welch, PK ^{[1
]}

Covington, M ^{[1
]}

Davies, P ^{[1
]}

Solomon, KA ^{[1
]}

Newton, RC ^{[1
]}

Trainor, GL ^{[1
]}

Decicco, CP ^{[1
]}

Ko, SK ^{[1
]}

机构：

[1] Bristol Myers Squibb Co, Expt Stn, Wilmington, DE 19880 USA

来源：

JOURNAL OF MEDICINAL CHEMISTRY | 2002年 / 45卷 / 17期

关键词：

D O I：

10.1021/jm0201767

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Structure-activity relationship (SAR) studies of initial screening hits from our corporate library of compounds and a structurally related series of CCR1 receptor antagonists were used to determine that an N-(alkyl)benzylpiperidine is an essential pharmacophore for selective CCR3 antagonists. Further SAR studies that introduced N-(ureidoalkyl) substituents improved the binding potency of these compounds from the micromolar to the low nanomolar range. This new series of compounds also displays highly potent, in vitro functional CCR3-mediated antagonism of eotaxin-induced Ca2+ mobilization and chemotaxis of human eosinophils.

引用

页码：3794 / 3804

页数：11

共 46 条

[1] BANYU PHARM CORP, 2000, Patent No. 0053600
[2] CCR3 blockade as a new therapy for asthma
Bertrand, CP
Ponath, PD
[J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2000, 9 (01) : 43 - 52
[3] EOSINOPHILIC INFLAMMATION IN ASTHMA
BOUSQUET, J
CHANEZ, P
LACOSTE, JY
BARNEON, G
GHAVANIAN, N
ENANDER, I
VENGE, P
AHLSTEDT, S
SIMONYLAFONTAINE, J
GODARD, P
MICHEL, FB
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 1990, 323 (15) : 1033 - 1039
[4] Corrigan C, 2000, Curr Opin Investig Drugs, V1, P321
[5] Cloning, expression, and characterization of the human eosinophil eotaxin receptor
Daugherty, BL
Siciliano, SJ
DeMartino, JA
Malkowitz, L
Sirotina, A
Springer, MS
[J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1996, 183 (05) : 2349 - 2354
[6] Discovery of potent and selective phenylalanine derived CCR3 receptor antagonists. Part 2
Dhanak, D
Christmann, LT
Darcy, MG
Keenan, RM
Knight, SD
Lee, J
Ridgers, LH
Sarau, HM
Shah, DH
White, JR
Zhang, LL
[J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2001, 11 (11) : 1445 - 1450
[7] Discovery of potent and selective phenylalanine derived CCR3 antagonists. Part 1
Dhanak, D
Christmann, LT
Darcy, MG
Jurewicz, AJ
Keenan, RM
Lee, J
Sarau, HM
Widdowson, KL
White, JR
[J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2001, 11 (11) : 1441 - 1444
[8] DUPONT PHARM, 2000, Patent No. [00035449, 0035449]
[9] DUPONT PHARM CO, 2000, Patent No. [0035877, 00035877]
[10] DUPONT PHARM CO, 2000, Patent No. [00035876, 0035876]

← 1 2 3 4 5 →